Skip to Content
Merck
All Photos(1)

Documents

11086090001

Roche

Calpain Inhibitor I

N-Acetyl-Leu-Leu-norleucinal, synthetic

Synonym(s):

Calpain Inhibitor I, n-acetyl-leu-leu-norleucinal, ALLN, Ac-LLnL-CHO, MG-101, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, N-Acetyl-Leu-Leu-Norleu-al

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H37N3O4
CAS Number:
Molecular Weight:
383.53
Beilstein:
7656053
MDL number:
UNSPSC Code:
12352204
PubChem Substance ID:

Quality Level

Assay

98% (chromatographically homogeneous)

form

powder

mol wt

Mr = 383.5

packaging

pkg of 25 mg

manufacturer/tradename

Roche

mp

182 °C

solubility

DMF: 10 mg/mL
ethanol: 10 mg/mL
methanol: 10 mg/mL

storage temp.

2-8°C

SMILES string

[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O

InChI

1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1

InChI key

FMYKJLXRRQTBOR-BZSNNMDCSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I and calpain II.

Specificity

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I (requiring 2–75 μM Ca2+ for activation) and calpain II (requiring 200–800 μM) with a Ki-value between 0.12 μM and 0.23 μM. Calpain II is inhibited to a lesser extent than calpain I. Calpain Inhibitor I is also a strong inhibitor of papain and cathepsin B and L. It shows only weak inhibition of cathepsin H and α-chymotrypsin and does not inhibit trypsin. ID50 for 0.02 U platelet calpain is 0.05 μM.

Application

Calpain inhibitor I inhibits calpain, which activates myosin light chain kinase and protein kinase C by partial proteolysis. The inhibitor should be membrane permeable due to low molecular weight and lack of charged residues.
Calpain Inhibitor I is used for western blotting methods.

Quality

Purity: 98% (from C); chromatographically homogeneous

Formula variant

C20H37N3O4

Preparation Note

Working concentration: 0.1 - 10 μM
The suggested starting concentration is 17 μg/ml. This is the concentration at which half maximal inhibition of calpain I is observed.
Working solution: Recommended solvent is DMF, ethanol, or methanol up to 10 mg/ml.
Storage conditions (working solution): -15 to -25 °C
Solutions in DMF, methanol, ethanol are stable for 4 weeks at -15 to -25 °C.

Reconstitution

Soluble in DMF, ethanol, or methanol to 10 mg/ml. For a stock solution, Roche recommends dissolving 1 mg of the inhibitor in 100 μl DMF, methanol, or ethanol. Before use, dilute with water or phosphate buffer (0.1 M, pH 7.5) to desired concentration. Solutions in DMF, ethanol, or methanol are stable for 2 to 3 days at 2 to 8 °C, and approximately 4 weeks at -15 to -25 °C. For best results, prepare solutions fresh before use.

Other Notes

For life science research only. Not for use in diagnostic procedures.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Takahisa Hirokawa et al.
International journal of molecular sciences, 22(15) (2021-08-08)
Tauopathies are neurodegenerative diseases characterized by abnormal metabolism of misfolded tau proteins and are progressive. Pathological phosphorylation of tau occurs in the retinal ganglion cells (RGCs) after optic nerve injuries. Cyclin-dependent kinase-5 (Cdk5) causes hyperphosphorylation of tau. To determine the
Erdinç Dursun et al.
Journal of Alzheimer's disease : JAD, 23(2), 207-219 (2010-10-23)
Amyloid-β (Aβ) is the core component of amyloid plaques of Alzheimer's disease (AD). The effects of Aβ include damage to neuronal plasma membrane, disruption of Ca(2+) homeostasis, and alterations of neurotrophic factor levels. The aim of this study was to
Sami Salmikangas et al.
Microorganisms, 8(12) (2020-12-10)
The current methods to study the distribution and dynamics of viral RNA molecules inside infected cells are not ideal, as electron microscopy and immunohistochemistry can only detect mature virions, and quantitative real-time PCR does not reveal localized distribution of RNAs.
Duygu Gezen-Ak et al.
PloS one, 6(3), e17553-e17553 (2011-03-17)
Recent studies have suggested that vitamin D can act on cells in the nervous system. Associations between polymorphisms in the vitamin D receptor (VDR), age-dependent cognitive decline, and insufficient serum 25 hydroxyvitamin D(3) levels in Alzheimer's patients and elderly people

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service